USPTO serial 98575628
AMACAGEL
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- STURMAN, JOSHUA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AMACAGEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Toronto, ON, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley M. Stohry
Bradley M. Stohry Reichel Stohry Dean LLP6151 Central AveIndianapolis, IN 46220United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Hydrogel for medical purposes, namely, hydrogel used as a delivery vehicle for therapeutic agents, enzymes, antibodies, cells, anesthetics, analgesics, anti-inflammatories, antihistamines, antibiotics, respiratory and lung preparations, cardiovascular preparations, central nervous system drugs, oncolytics, anti-cancer preparations, lipid nanoparticles, metal salts, immunomodulators, immunosuppressives, immunogenic particles, vaccines, thyroid preparations, gene therapy preparations, peptides and peptide mimetics, hormones, steroids, vitamins, growth factors, and nucleic acid molecules; Hydrogel polymer matrix comprising hyaluronic acid and methyl cellulose for medical therapeutic purposes; Hydrogel for medical purposes, namely, injectable hydrogel for the prevention of fibrosis; Injectable local anesthetic, namely, injectable hydrogel comprising hyaluronic acid and methyl cellulose for medical purposes; human vaccine preparations; pharmaceutical preparations for use in gene therapy; veterinary vaccines | ACTIVE | — |
| 040 | Drug manufacturing services, namely, custom manufacture of pharmaceuticals by pharmaceutical compounders | ACTIVE | — |
| 042 | Pharmaceutical drug development services; pharmaceutical research and development; Drug development services, namely, development of dermatological drugs | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 15, 2026 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Oct 15, 2026 | RGIA | REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED | — |
| Oct 15, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 15, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 24, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 26, 2026 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 26, 2026 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 26, 2026 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 19, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 19, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 19, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 19, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 18, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 18, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 18, 2025 | ALIE | ASSIGNED TO LIE | — |
| Dec 10, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 24, 2025 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Sep 24, 2025 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Sep 24, 2025 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Sep 19, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 17, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 17, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 17, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 16, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 30, 2024 | NWAP | NEW APPLICATION ENTERED | — |